Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
Volume 1.50M
Average 2.02M
NMRA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA
Depreciation & Amortization Β· Q1 FY2026 Β· quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $8K fell 94.9% year over year, behind the -90.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 11.1% from the prior quarter. Over 3 fiscal years it compounded at -29.5% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -94.9% toward the trailing-twelve-month pace of -90.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD Β· from the income statement
- Latest Β· FY2025
- 208K USD
- Year-over-year change
- -67.0%
- 4-year CAGR
- -21.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 208K | -67.0% |
| FY2024 | 2024-12-31 | 631K | -5.5% |
| FY2023 | 2023-12-31 | 668K | +12.5% |
| FY2022 | 2022-12-31 | 594K | +10.4% |
| FY2021 | 2021-12-31 | 538K | β |
Depreciation & Amortization vs competitors
How NMRA compares with its peers on the latest reported figures
- NMRA's LTM Mar 2026 depreciation & amortization of $59K is the lowest of the 10 companies compared; the peer median is $2.31M.
- Its year-over-year change of -90.6% is the lowest of 10, against a peer median of -6.3%.
- Over three fiscal years its annual growth of -29.5% compares with a peer median of +13.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13M | +24.1% | +9.8% | 14.0% | |
| LTM Mar 2026 | $6.46M | +0.4% | +46.9% | 7.3% | |
| LTM Mar 2026 | $5.92M | -17.6% | +20.3% | 9.3% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $2.65M | -20.7% | +140.9% | 35.9% |
| LTM Mar 2026 | $2.31M | +156.8% | +70.7% | 4.0% | |
| LTM Mar 2026 | $1.38M | -6.3% | -16.8% | β | |
| LTM Mar 2026 | $1.19M | -63.3% | -7.7% | 1.5% | |
| LTM Mar 2026 | $914K | -11.7% | +0.4% | 9.2% | |
| LTM Mar 2026 | $555K | -1.9% | +13.3% | 0.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | β |
| Peer median (excluding NMRA) | $2.31M | -6.3% | +13.3% | 8.3% | |
Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 0 | 5M |
| Gross Profit | 0 | 0 | (668K) | 0 | (5M) |
| Gross Margin | β | β | β | β | β |
| Research & Development | 212.78M | 104.75M | 142.72M | 200.93M | 176.07M |
| Selling, General & Admin | 24.55M | 31.12M | 44.81M | 62.54M | 60.09M |
| Operating Expenses | 237.32M | 135.87M | 187.53M | 263.46M | 236.16M |
| Depreciation & Amortization | 538K | 594K | 668K | 631K | 208K |
| EBITDA | (236.77M) | (130.31M) | (234.99M) | (242.98M) | (233.37M) |
| EBITDA Margin | β | β | β | β | β |
| Operating Income | (237.32M) | (135.87M) | (188.19M) | (263.46M) | (241.16M) |
| Operating Margin | β | β | β | β | β |
| Interest Income | 0 | 4.56M | 16.61M | 19.93M | 8.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 3.22M |
| Other Income / Expenses | 11K | 4.97M | (47.46M) | 19.86M | 4.36M |
| Income Before Tax | (237.31M) | (130.9M) | (235.66M) | (243.61M) | (236.8M) |
| Pre-Tax Margin | β | β | β | β | β |
| Income Tax Expense | 0 | 0 | 268K | 178K | 130K |
| Net Income | (237.31M) | (130.9M) | (235.93M) | (243.79M) | (236.93M) |
| Net Margin | β | β | β | β | β |
| EPS (Basic) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| EPS (Diluted) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| Weighted Avg Shares | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
| Weighted Avg Shares (Diluted) | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.